柔肝归魂法对卒中后抑郁状态的干预临床疗效观察

Clinical efficacy observation on treating PSD by Rougan Guihun therapy

目的:观察柔肝归魂法治疗卒中后抑郁的临床疗效。方法:采用开放式随机对照方法,将87例患者分为两组,分别用柔肝归魂法(治疗组45例)和百忧解(对照组42例)治疗4周,于治疗前后应用汉密尔顿抑郁量表(HAMD)、自拟中医证候等级评分量表评定药物疗效,并同时观察药物不良反应。结果:两组临床疗效比较差异无显著性(P>0.05);两组治疗后HAMD积分均明显低于治疗前(P<0.05),两组间比较差异无显著性(P>0.05);在改善中医证候方面,治疗组优于对照组(P<0.05);治疗组不良反应明显低于对照组。结论:柔肝归魂法对卒中后抑郁的临床疗效与百忧解相当;缓解躯体症状优于百忧解;无明显不良反应。

Objective： To observe the efficacy ofRougan Guihun therapy on treating post-stroke depression （PSD）. Methods： Using open randomized controlled method, 87 patients were divided into two groups, using Rougan Guihun therapy （treated group 45 cases） and prozac （control group 42 cases）, 4 weeks treatment in the application before and after treatment to Hamilton depressive scale （HAMD）, the TCM syndrome grade rating scale to assess efficacy, and at the same time observe the adverse drug reactions. Results： There was no significant difference compared two groups of clinical curative effect （P〉0.05）. Two groups of HAMD score after treatment were significantly lower than before treatment （P〈0.05）, there was no significant difference is compared between two groups （/9〉0.05）. In terms of improving syndromes, the treated group is better than that of control group （P〈0.05）. Adverse reactions of treated group were obviously lower than the control group. Conclusion： Rougan Guihun therapy has the better clinical curative effect on treating PSD than Prozac. Alleviate symptoms of body is better than that of Prozac, no obvious adverse reactions.